CELL ORIGINS, LLC

Biotech · Private

A diagnostic kit using bacteriophage virions with surface-displayed peptides and ssDNA tags to simultaneously profile mRNA and cell surface biomarkers for cell line identity and quality control

Grants
$150K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
3
0 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Cell Line Identification and Characterization by Dual Targeting of Phenotypic Markers$149,980
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1608RIBO-THERAPEUTICS LLC——
1609Yuva Biosciences, Inc.—$1.1M
1610CEL-SCI CORPORATION—$1.1M
1611CELL ORIGINS, LLC——
1612GATC HEALTH CORP—$981K
1613DIVERSE BIOTECH, INC.—$669K
1614XORTX Therapeutics Inc.—$505K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 3
  • Reagents And Methods For Cell Identification And Characterizationapplication
  • Reagents And Methods For Cell Identification And Characterizationapplication
  • Reagents And Methods For Cell Identification And Characterizationapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.